IQVIA„¢ (NYSE: IQV) today announced the launch of a patented technology platform that advances real-world research and protects genomic data privacy. E360„¢ Genomics, a scalable, privacy-preserving genotypic-phenotypic database solution, provides an efficient way to conduct genomic research with genomic and clinical databases.
Genomic data are critical to transforming clinical research and healthcare delivery, said Jon Resnick, president, Real-World & Analytics Solutions at IQVIA. This game-changing technology will be a significant catalyst for scientific discovery, and improved patient outcomes. It offers researchers more efficient and cost effective access to genomic data while addressing privacy concerns.
E360 Genomics platform enables life science customers immediate access to aggregated data at scale to conduct a wide range of research including association studies of genomics and observable traits, comparative efficacy and safety trials, and burden-of-illness and discovery analytics using non-identified data in a secure environment that protects patients privacy. IQVIAs patented techniques allow for the removal of phenotypic, identifying information from genomic data while retaining the critical linkage of clinical and genomics data to improve research and healthcare delivery. The result is a more flexible and less expensive approach for scientific inquiry into human biology, drug discovery, and drug development.
Powered by IQVIA CORE„¢, the E360 Genomics platform can manage the scale and complexity of genomic datasets and draw insights from a significantly increased number of covariates while preserving privacy. IQVIA CORE brings together a dynamic integration of unparalleled data, transformative technology, advanced analytics and essential domain expertise. IQVIA is committed to advancing global public health by integrating data science and technology with human science expertise to drive new discoveries and insights from increasingly large and complex datasets.
Additional information about the E360 Genomics platform is available at E360„¢ Genomics.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIAs insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.